Sarcoma vaccine - MabVax/MSKCC

Drug Profile

Sarcoma vaccine - MabVax/MSKCC

Alternative Names: MV-Sarc

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines; Monoclonal antibodies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Sarcoma

Most Recent Events

  • 10 Mar 2017 MabVax Therapeutics completes a phase II trial in Sarcoma in USA (SC) (NCT01141491)
  • 07 Apr 2015 Phase II development is ongoing in USA
  • 08 Jul 2014 MabVax Therapeutics merged with a wholly-owned subsidiary of Telik
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top